möglich sobald bei der ZB eingereicht worden ist.
Modeling human liver cancer heterogeneity: Virally induced transgenic models and mouse genetic models of chronic liver inflammation.
Curr. Protoc. Pharmacol. 67, 14.31.1-14.31.17 (2014)
In addition to being the most common primary liver cancer, hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in humans. Treatment options are limited for this chemoresistant cancer, with liver transplantation and surgical intervention in early stages being the most successful treatments. Drug development over the past 15 years has focused on generating mouse models that mimic the human pathology for HCC. This has enabled the laboratory testing of potentially new human therapeutics. Described in this unit are the classification of HCC and an overview of hepatitis virus-related transgenic and genetically engineered mouse models (GEMMs) that are employed for elucidating the mechanism(s) responsible for the development of HCC, with particular emphasis on genetic, dietary, and environmental factors.
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Hcc ; Chronic Liver Inflammation ; Liver Cancer ; Modeling Human Disease ; Mouse Model
ISSN (print) / ISBN 1934-8282
Zeitschrift Current Protocols in Pharmacology
Quellenangaben Band: 67, Seiten: 14.31.1-14.31.17
Verlagsort New York, NY [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)